{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:20:45Z","timestamp":1761513645655,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.seizure.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T05:25:44Z","timestamp":1433741144000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and safety of ezogabine\/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures"],"prefix":"10.1016","volume":"30","author":[{"given":"Holger","family":"Lerche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narinder","family":"Lotay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"DeRossett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1640","authenticated-orcid":false,"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2015.06.002_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2005.tb00033.x","article-title":"Retigabine: chemical synthesis to clinical application","volume":"11","author":"Blackburn-Munro","year":"2005","journal-title":"CNS Drug Rev"},{"year":"2013","series-title":"Trobalt summary of product characteristics","author":"GlaxoSmithKline","key":"10.1016\/j.seizure.2015.06.002_bib0105"},{"year":"2012","series-title":"POTIGA\u2122 prescribing information","author":"GlaxoSmithKline","key":"10.1016\/j.seizure.2015.06.002_bib0110"},{"key":"10.1016\/j.seizure.2015.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(06)68477-8","article-title":"Adult epilepsy","volume":"367","author":"Duncan","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2015.06.002_bib0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2015.06.002_bib0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2012.06.005","article-title":"Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials","volume":"103","author":"Gao","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2015.06.002_bib0130","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.06.002_bib0135","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.06.002_bib0140","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.06.002_bib0145","series-title":"63rd Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii","article-title":"Efficacy of adjunctive ezogabine (retigabine) 600\u20131200mg\/day by concomitant antiepileptic drug in adults with drug-resistant partial-onset seizures","author":"Leroy","year":"2011"},{"key":"10.1016\/j.seizure.2015.06.002_bib0150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1734-1140(09)70024-6","article-title":"Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions","volume":"61","author":"Luszczki","year":"2009","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.seizure.2015.06.002_bib0155","unstructured":"FDA, FDA drug safety communication: anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration, Available from URL: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm349538.htm. 2013 [cited 2014 Nov 11]."},{"key":"10.1016\/j.seizure.2015.06.002_bib0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.06.002_bib0165","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2015.06.002_bib0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs \u2013 rational polytherapy","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2015.06.002_bib0175","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2015.06.002_bib0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eplepsyres.2013.08.021","article-title":"Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures","volume":"107","author":"Biton","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2015.06.002_bib0185","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/01.ju.0000138155.33749.f4","article-title":"Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats","volume":"172","author":"Streng","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.seizure.2015.06.002_bib0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131115001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:45:57Z","timestamp":1761011157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131115001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":19,"alternative-id":["S1059131115001491"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2015.06.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ezogabine\/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}